Homepage0775 • HKG
add
CK Life Sciences Intl (Holdings) Inc
Vorige slotkoers
$Â 0,86
Dag-range
$Â 0,84 - $Â 0,86
Jaar-range
$Â 0,32 - $Â 1,10
Beurswaarde
8,07Â mld. HKD
Gem. volume
24,65Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
HKG
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (HKD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,44Â mld. | 5,22% |
Bedrijfskosten | 484,04Â mln. | 31,22% |
Netto inkomsten | -63,78Â mln. | -548,74% |
Netto winstmarge | -4,42 | -513,89% |
Winst per aandeel | — | — |
EBITDA | 4,85Â mln. | -95,35% |
Effectief belastingtarief | -32,21% | — |
Balans
Totale activa
Totale passiva
| (HKD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 571,21Â mln. | -15,52% |
Totale activa | 10,79Â mld. | -4,08% |
Totale passiva | 7,28Â mld. | 3,10% |
Totaal aandelenvermogen | 3,51 mld. | — |
Uitstaande aandelen | 9,61 mld. | — |
Koers-boekwaardeverhouding | 2,32 | — |
Rendement op activa | -0,87% | — |
Rendement op kapitaal | -0,97% | — |
Kasstroom
Nettomutatie in liquide middelen
| (HKD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -63,78Â mln. | -548,74% |
Operationele kasstroom | 104,07Â mln. | -52,01% |
Kasstroom uit beleggingen | -441,00K | 98,29% |
Kasstroom uit financiering | -93,26Â mln. | 12,31% |
Nettomutatie in liquide middelen | 2,38Â mln. | -97,21% |
Vrije kasstroom | 4,79Â mln. | 136,38% |
Over
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
CEO
Opgericht
2000
Website
Werknemers
2.033
